MARGINAL ZONE LYMPHOMA

This study tests a new vaccine (EO2463) designed to help the immune system fight indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. About 80 adults with follicular or marginal zone lymphoma will receive the vaccine alone or combined with standard drugs lenalidomide and…

This early-stage trial tests an experimental drug called ICP-248, taken as a pill, for people with B-cell blood cancers like leukemia and lymphoma. The study will see if the drug is safe, what dose works best, and whether it helps shrink tumors. About 191 adults aged 18 to 80 are…

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This early-stage trial tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two other treatments. The study aims to find the safest dose and check…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participant…

This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…

This phase II trial tests the drug pemigatinib (Pemazyre) in 27 adults with relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell and marginal zone lymphoma. Participants take one pill daily in 28-day cycles. The main goal is to see if the drug can shrink tum…

This Phase 3 trial is testing whether a combination of two drugs, mosunetuzumab and lenalidomide, works better than standard treatments for people with marginal zone lymphoma that has come back or not responded to previous therapy. About 260 participants will be randomly assigned…

This early-phase study tests a new treatment called JV-213 for adults with B-cell lymphoma that has come back or not responded to other treatments. JV-213 uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor si…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This study tests whether the investigational drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. About 25 adults will receive the drug and be monitored for complete remission after 12 cycles. The goal is to see if this treatm…

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This study looks at a two-drug combination (zanubrutinib and rituximab) as a first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 participants will receive the combo to see how well it shrinks tumors and delays the cancer from getting wors…

This study compares a very low dose of radiation (4 Gy) to the standard dose (24 Gy) for people with follicular or marginal zone lymphoma, two slow-growing types of blood cancer. The goal is to see if the lower dose works just as well at controlling the cancer while causing fewer…

This study tests a new drug called orelabrutinib combined with chemotherapy for people newly diagnosed with marginal zone lymphoma, a rare blood cancer. Researchers want to see if the combination helps shrink tumors and keeps the cancer from coming back. The trial includes two gr…

This phase 2 study is testing whether combining rituximab (an antibody) with venetoclax (a targeted pill) can improve outcomes for people with untreated marginal zone lymphoma. About 33 participants will receive the combination, and researchers will measure how many achieve a com…

This early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's…

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and to see how the drug behaves in the body…

This study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…

This study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …

This study tests two drugs, mosunetuzumab and lenalidomide, as the first treatment for people with follicular or marginal zone lymphoma. About 52 adults will receive the drugs in cycles, with the dose adjusted based on how well the cancer responds. The goal is to see how many pat…

This study tests a drug called loncastuximab tesirine in about 50 adults with marginal zone lymphoma that has returned or not responded to prior treatments. The goal is to see if the drug can shrink or eliminate the cancer, while monitoring side effects. Participants receive the …

This study tests a new drug called CHO-H01, alone or with another drug (lenalidomide), in people with a type of blood cancer called non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink…

This early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like leukemia or lymphoma) that returned or didn't respond to prior treatments. The main goals are to find a safe dose and understand side effects. Researchers will also check how …

This study tests a combination of two drugs, rituximab and zanubrutinib, in people with untreated follicular lymphoma or marginal zone lymphoma. The goal is to see if the combination is safe and effective at shrinking or controlling the cancer. About 43 participants will receive …

This early-phase trial tests an experimental daily pill, LP-168, in about 200 adults whose B-cell lymphoma has returned or not responded to standard treatments. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors …

This early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…

This study tests a drug called orelabrutinib in 30 people with a slow-growing blood cancer called marginal zone lymphoma who have not had any prior treatment. The goal is to see if the drug can shrink or control the cancer. Participants take the drug by mouth and are monitored fo…

This study tests whether combining two drugs, mosunetuzumab and zanubrutinib, can safely control marginal zone lymphoma that has returned or stopped responding to prior treatment. About 36 adults with stage II–IV disease will receive the combination. The goal is to see how well t…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with B cell cancers like lymphoma or leukemia that have come back or not responded to prior treatments. The goal is to see if this therapy is safe and eff…

This study compares two drug combinations in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. One group receives zanubrutinib plus obinutuzumab or rituximab, while the other gets lenalidomide plus rituximab. The goal is to se…

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This study tests an experimental oral drug called MK-1026 (nemtabrutinib) in people with certain blood cancers, including chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink or control the cancer and t…

This study tests whether two drugs, pirtobrutinib and rituximab, can shrink or eliminate tumors in people newly diagnosed with marginal zone lymphoma. About 23 adults will receive the combination and be checked for response after several cycles. The goal is to control the disease…

This study tests whether a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) can safely shrink tumors in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. About 45 adults who have already tried at…

This early-stage study tests a new gene therapy called VNX-101 for people with blood cancers (like some leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system target and…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study looks at how often high blood pressure happens in people with certain blood cancers (like CLL or lymphoma) who are taking a type of targeted drug called a BTK inhibitor. The goal is to see if carefully managing that high blood pressure can reduce the risk of serious he…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those wh…

This study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib (with or without obinutuzumab) as part of their normal care. Researchers will track hospital visits, qualit…

This study will follow 2,500 people newly diagnosed with marginal zone B-cell lymphoma to better understand the disease and how different treatments affect it. Researchers will track how long patients live without the cancer getting worse and how well various therapies work. The …

This study follows 150 adults aged 70 and older with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to track well-being from diagnosis through one year after therapy starts. The goal is to identify whi…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…